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EX-VIVO DETECTION OF CD8 T-CELL RESPONSES TO IN-SILICO PRE-
DICTED HY MINOR HISTOCOMPATIBILITY ANTIGENS (mHAg) FOLLOW-
ING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HCT)
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Minor histocompatibility antigens (mHAg) genes located on the Y
chromosome (HY) differ substantially from homologs on the 
chromosome (HX). Thus immunologic disparities occur in alloge-
neic HCT from female donor to male recipient (FtoM) and may ex-
plain the FtoM association with GVHD. Using in-silico prediction
tools, we chose and synthesized 24 HY peptides (9-10mers) that
bind HLA A0201 by T2 cell binding assay, yet differ in sequence
from HX.With IRB approval, we collected one-time blood samples
at 2 months-5 years post-HCT from adult male recipients. The pri-
mary group had HLA-A21 female donor (n 5 29); controls had
HLA-A21 male donor (n 5 18) or nonHLA-A21 female donor (n
5 14). Additional controls were HLA-A21 female nonpatients (n
5 25); none was a donor. Expression of CD137 in CD8 T cells
was measured by flow-cytometry after 24-hour stimulation of
PBMC with one of 2 pools (I, II) of 12 HY peptides each. PBMCs
exposed to media alone or CEF (CMV, EBV, influenza) peptides
were negative and positive control, respectively. Response to HY
peptide pool (minus response to media alone) was considered posi-
tive if above 0.07%. A majority of CD1371CD81 cells had
CD45RA1CD27- cytolytic effector profiles. CD8 responses to
a few peptides were shared among multiple patients (i.e.
LLLHCPSKTV derived from DFFRY, KLCKVRKITV from
RPS4Y, and a previously described mHAg, FIDSYICQV, from
SMCY). Positive response was more frequently observed in FtoM
HLA-A21 subjects than in controls combined, a finding more sig-
nificant for responses to pool I (27.6% vs 7.0% 1, p\ 0.01) than
to pool II (31.0% vs 15.8% 1, p 5 0.10). Agreement between cate-
gorical responses to pools I and II was 41.8% (95%CI 5.9%-77.8%)
better than by chance among FtoMHLA-A21 subjects but no better
than chance in each control group. Continuous responses to pools I
and II were not correlated in any group. FtoMHLA-A21 recipients
had 1.47-fold (95% CI 1.05-2.05) higher continuous response to
pool I than did all controls combined. A similar association was
not present for response to pool II. Independent effects of time since
HCT, history of GVHD, current immunosuppressive therapy, and
characteristics of donor and recipient on CD8 responses to HY pep-
tides will be presented. In summary, novel HLA-A0201-restricted
HY mHAg were predicted and validated in HCT patients. Our
data may facilitate identification of clinically relevant immune tar-
gets of GVHD/GVL, and a biomarker for risk of GVHD based on
CD8 responses to mHAg.215
IMMUNE RECONSTITUTION AFTER DOUBLE UMBILICAL CORD BLOOD
STEM CELL TRANSPLANTATION: COMPARISON WITH PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION
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Patients who undergo umbilical cord blood (UCB) stem cell trans-
plantation are at high risk of developing infectious complications. To
define the immunologic deficiencies associated with UCB transplan-
tation we compared immune reconstitution in patients who received
either UCB stem cells (n5 42) or G-CSFmobilized blood stem cells
from HLA-matched unrelated donors (MUD) (n 5 102). All UCB
recipients received 2 partially HLA-mismatched products; all pa-
tients received non-myeloablative conditioning. Blood samples
were analyzed at 1, 3, 6, 9, 12, 18, and 24 months post-transplant
for T, B, and NK cell surface markers, immunoglobulin levels, and
B cell activating factor (BAFF) levels.
Reconstitution of CD31 cells was significantly delayed in UCB
compared to MUD for 1-6 months post-transplant (p \ 0.001).This included naive (CD41CD45RO-) and memory
(CD41CD45RO1) CD4 T cells, regulatory (CD41CD251) T
cells, and CD81 T cells. In contrast, CD191 B cells recovered
more rapidly in the UCB group and remained significantly greater
from 3-24 months post-transplant (p 5 0.001). CD561CD161
NK cells also recovered more rapidly in UCB patients and remained
significantly greater from 1-24months post-transplant. IgG and IgM
levels recovered to normal range by 4-6 months, but IgA levels re-
mained below normal during the follow-up period. BAFF levels
were significantly higher in the UCB cohort at 1 month (p \
0.001) but were similar at 3 and 6 months. Despite similar BAFF
levels, BAFF/CD19 B cell ratios were significantly lower in the
UCB cohort at 3 (p 5 0.004) and 6 months (p 5 0.005).
This comparison of immune reconstitution after UCB and MUD
transplantation in adults demonstrates that recovery of all T cells and
T cell subsets is significantly delayed for a 6 month period while B
and NK cell recovery is actually more rapid following UCB. UCB
B cells appear to function normally resulting in early recovery of
IgG and IgM levels. Higher BAFF levels early post-transplant in
UCB patients may be responsible for the rapid and sustained B cell
recovery but reasons for the delayed T cell recovery are not known.
Early reconstitution of B cells, resolution of high BAFF levels, and
reduced BAFF/B cell ratio in UCB patients who survive to T cell re-
constitution may contribute to the reduced incidence of chronic
GVHD (p\0.001) in this group. Increased infectious complications
followingUCBT appear to be primarily due to selective global T cell
deficiency in the first 6 months post-transplant.216
LIVER IMMUNITY HAS PROTECTIVE FUNCTIONS AFTER HEMATOPOIETIC
CELL TRANSPLANTATION BUT CAN CONTRIBUTE TO REJECTION OF THE
GRAFT
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The liver is a critical immunocompetent organ that contains lym-
phocytes, natural killer (NK) cells, and antigen-presenting cells, in-
cluding Kupffer cells, the resident macrophages. Because the liver is
exposed to a variety of antigens as well as destructive and harmless
toxins, it must provide immunogenic and tolerogenic immunity.
Here, we studied the role of the liver on host protective immunity
and donor engraftment post hematopoietic cell transplantation
(HCT). Lethally irradiated BALB.b and BALB.k mice received
MHC-matched FACS-purified hematopoietic stem cells (HSC)
1/- splenocytes (SP) fromC57BL/6 (B6,H2b) and AKR/J (H2k) do-
nors, respectively. Frozen tissue and Ficoll-separated mononuclear
cells (MNC) from livers, marrow, and blood were analyzed. Recipi-
ents of HSC1SP developed acute graft-versus-host disease
(GVHD). The liver was a major target organ with massive donor
T cell (TC) infiltration. However, lead-shielding of livers only dur-
ing conditioning with total body irradiation completely protected
mice from lethal GVHD. No infiltrating donor TC were detectable
in unirradiated livers, however, donor engraftment was completely
prevented. Examination of themarrows of thesemice revealed donor
cells comprised 3-10% of live cells on day 7 post-HCT, which were
subsequently rejected. This observation implies that the liver con-
tains immune cells that contribute to graft rejection. To test if this
graft loss was due to alloreactivity GFP.B6 donor cells were infused
into syngeneic B6 mice that were irradiated with/without liver
shielding. Again, shielding of livers resulted in graft loss. In contrast,
shielding of other body parts, such as legs, did not prevent donor cell
engraftment. To clarify which cell populations mediate graft resis-
tance, B- and TC deficient Rag2-KO and B-, T,- and NK cell defi-
cient Rag2gc-KO mice were used as recipients. The median % of
donor granulocytes in liver shielded Rag2- and Rag2c-KO was
16% and 31%, respectively, which is higher than in unirradiated,
but significantly lower than in fully irradiated KO controls. The ob-
servation that lymphocyte deficient mice that received liver shielding
could resist donor engraftment implies that non-lymphoid cells, i.e,
those of the innate immune system play a central role in HSC resis-
tance. In conclusion, our data highlight the importance of the liver in
mediating engraftment of HSC, a feature that may often be over-
looked as the liver is also major target of donor TC during acute
GVHD.
